Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors
ATLANTA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is...
News
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
Drug overdoses are the leading cause of death for those under age 50SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) --...
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523
Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of CancerCHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE)...
Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and...
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
- Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into...
Clinical data published in Clinical Microbiology and Infection support use of MeMed’s test in reducing antibiotic overuse in children
Clinical data published in Clinical Microbiology and Infection support use of MeMed’s test in reducing antibiotic overuse in children The...
G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor Microenvironment
New Trial Designed to Further Investigate the Immune-Based MOA of Trilaciclib and Help Determine Future Target Tumor Types and Treatment...
BioXcel Therapeutics Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders
PDUFA date extended by three months to April 5, 2022 No Additional Data Requested Following Meeting with FDA NEW HAVEN,...
Surface Oncology Announces FDA Clearance of IND Application for GSK4381562, a Novel Antibody Targeting PVRIG
Surface to receive $30 million milestone payment upon first patient treated in the Phase 1 studyCAMBRIDGE, Mass., Dec. 01, 2021...
Clene Nanomedicine Presents Updated Data from RESCUE-ALS Phase 2 Study at 4th Annual ALS ONE Research Symposium
CNM-Au8 has favorable impact on progression of ALS as measured by joint rank comparison of combined survival and ALSFRS-R change...
Origin Therapeutics Portfolio Company Tripsitter has Commenced Trading on the Canadian Securities Exchange
Vancouver, B.C, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (the “Company” or “Origin Therapeutics”) an actively managed...
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated...
Philips expands Augmented Reality Surgical Navigation – ClarifEye – to two new international sites with successful clinical outcomes
Philips ClarifEye AR at Armed Forces Hospital Oman Philips ClarifEye AR at Sant Joan de Déu Barcelona Children's Hospital Spain...
Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement
MIAMI, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing...
Completion of accelerated bookbuild offering of existing shares in NTG Nordic Transport Group A/S
Company announcement no. 24 - 211 December 2021 NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA. THE...
Clinical data published in Clinical Microbiology and Infection support use of MeMed’s test in reducing antibiotic overuse in children
Clinical data published in Clinical Microbiology and Infection support use of MeMed’s test in reducing antibiotic overuse in children The...
First Evidence of High-Dose Methotrexate Related Toxicity in Spain Presented at Virtual ISPOR Europe 2021
COPENHAGEN, Denmark, Dec. 01, 2021 (GLOBE NEWSWIRE) -- The first evidence of high dose methotrexate related toxicity (HDMTX) in Spain...
Therma Bright Expands Manufacturing Capabilities To Meet New FDA EUA Guidance For AcuVid(TM)
Agreement with Contract Manufacturer Provides for Production of 500,000 AcuVid(TM) Tests Per WeekToronto, Ontario--(Newsfile Corp. - December 1, 2021) -...
Psyched Wellness Presents AME-1 to Health Canada in Pre-Submission Meeting
Toronto, Ontario--(Newsfile Corp. - December 1, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or...
LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference
LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the 4th International Brain...